Sangamo Therapeutics (SGMO)
0.8292 -0.0108 (-1.29%) 14:24 ET [NASDAQ]
0.8285 x 200 0.8301 x 200
Realtime by (Cboe BZX)
0.8285 x 200 0.8301 x 200
Realtime 0.8499 +0.0107 (-) 09:29 ET
for Wed, Mar 26th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Cash Flows From Operating Activities | |||||
Net Income | -97,941 | -257,831 | -192,278 | -178,297 | -121,122 |
Depreciation Amortization | 9,088 | 109,348 | 19,320 | 20,482 | 12,544 |
Income taxes - deferred | 0 | -6,335 | 0 | 0 | N/A |
Accounts receivable | 397 | 2,755 | 1,890 | -103 | 31,332 |
Other Working Capital | 3,951 | -160,303 | -82,319 | -101,895 | 252,586 |
Other Operating Activity | 17,366 | 87,524 | 29,760 | 26,562 | -5,465 |
Operating Cash Flow | $-67,139 | $-224,842 | $-223,627 | $-233,251 | $169,875 |
Cash Flows From Investing Activities | |||||
Change In Deposits | 35,840 | 174,686 | 79,456 | 271,596 | -256,209 |
PPE Investments | -267 | -21,155 | -20,171 | -23,278 | -14,714 |
Purchase Of Investment | N/A | N/A | 0 | -119 | -704 |
Other Investing Activity | 1,951 | 0 | 0 | 0 | 0 |
Investing Cash Flow | $37,524 | $153,531 | $59,285 | $248,199 | $-271,627 |
Cash Flows From Financing Activities | |||||
Common Stock Issued | 29,281 | 16,041 | 86,764 | 36,116 | 153,865 |
Other Financing Activity | -904 | -1,453 | -2,104 | -3,258 | -765 |
Financing Cash Flow | $28,377 | $14,588 | $84,660 | $32,858 | $153,100 |
Exchange Rate Effect | -2,048 | 1,483 | 1,254 | -263 | -447 |
Beginning Cash Position | 46,704 | 101,944 | 180,372 | 132,829 | 81,928 |
End Cash Position | 43,418 | 46,704 | 101,944 | 180,372 | 132,829 |
Net Cash Flow | $-3,286 | $-55,240 | $-78,428 | $47,543 | $50,901 |
Free Cash Flow | |||||
Operating Cash Flow | -67,139 | -224,842 | -223,627 | -233,251 | 169,875 |
Capital Expenditure | -267 | -21,155 | -20,171 | -23,278 | -14,714 |
Free Cash Flow | -67,406 | -245,997 | -243,798 | -256,529 | 155,161 |